Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
November 08, 2023
Lead Product(s) : 177-Lu Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Advanced Accelerator Applications
Deal Size : $172.0 million
Deal Type : Agreement
Details : Advanced Accelerator Applications (AAA) and Endocyte, Inc., both Novartis companies, successfully completed full-scale development of Pluvicto and also received Breakthrough Therapy designation from the U.S. FDA last year.
Product Name : Pluvicto
Product Type : Radiolabeled Compounds
Upfront Cash : $12.0 million
March 29, 2022
Lead Product(s) : 177-Lu Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Advanced Accelerator Applications
Deal Size : $172.0 million
Deal Type : Agreement
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
February 08, 2021
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
September 25, 2019
Reset All
